An illustration of a tumor cell cluster

credit: julie davie

Uncovering unknown tumor antigens

Detecting tumor antigens is key to developing effective cancer diagnostics, immunotherapies, and vaccines.
Tiffany Garbutt, PhD Headshot
| 2 min read

Download the infographic here.

Uncovering unknown tumor antigens
by tiffany garbutt, phd, illustrated by Julie Davie

Tumor antigens are proteins or molecules presented on the surface of tumor cells by the major histocompatibility complex (MHC) that stimulate an immune response in the body. Detecting tumor antigens is key to developing effective cancer diagnostics, immunotherapies, and vaccines. Many antigens that define specific cancer types at the population and individual levels remain a mystery, spurring researchers to hunt for more effective ways to identify them.

Tumor-associated antigens (TAAs)

TAAs are normal proteins, such as germline proteins, that are overexpressed in cancer cells. Because TAAs are also expressed in normal tissues, immunotherapies targeting TAAs may not elicit effective antitumor responses and pose the risk of inducing autoimmunity (1).

Tumor-specific antigens (TSAs)

TSAs are exclusive to cancer cells. They result from genetic alterations that produce new proteins or from antigens derived from oncoviruses or endogenous retroviral elements. Because TSAs are unique, identifying these antigens requires combining high throughput genomics and proteomics, which is difficult to do on a large scale (1).

Unbiased tumor antigen screening

With unbiased tumor antigen screening, researchers perform whole exome sequencing on excised tumors to identify single nucleotide variants and small genomic insertions and deletions. They then create pooled antigen libraries and pulse them into antigen-presenting cells, thereby exposing the antigens to all possible MHC molecules. They then coculture the cells with tumor infiltrating-lymphocytes to detect which antigen pools elicit T cell activation (2).

Prediction algorithms

Several machine learning algorithms trained on experimental data can artificially generate antigens derived from different proteins and predict their ability to bind specific MHC molecules that would trigger T cell responses. However, it is important to experimentally validate algorithm predictions for immunogenicity (2).

Immunopeptidomics

Immunopeptidomics involves eluting antigens from their complexes with MHC molecules and running them through liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) columns. To identify tumor antigens, researchers then compare the LC-MS/MS spectra to custom databases containing next generation sequencing (NGS) data from tumors with reference protein sequences. While LC-MS/MS is better at capturing post-translational modifications, it has limited sensitivity and several biases (2).

Complimentary DNA (cDNA) expression library screening

cDNA expression library screening involves isolating total RNA from tumor cells and converting it into cDNA plasmids that are then transfected into cell lines in culture. Researchers then coculture the cells with isolated tumor reactive T cells and screen for which cDNA plasmids elicit a T cell response (2).

Next generation sequencing (NGS)

NGS approaches involve sequencing DNA or RNA from normal and cancerous tissue and using bioinformatic algorithms to identify altered genomic regions. However, some NGS approaches such as whole exome sequencing may miss alternatively spliced TSAs (3). As such, NGS is best paired with immunopeptidomes approaches (2).

References

  1. Buonaguro, L., & Tagliamonte, M. Selecting target antigens for cancer vaccine development. Vaccines  8, 615 (2020).
  2. Leko, V., & Rosenberg, S.A. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell  38, 454-472 (2020).
  3. Haen, S.P., Lo¡er, M.W., Rammensee H-G, & Brossart, P. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat Rev  17, 595-610 (2020).

About the Author

  • Tiffany Garbutt, PhD Headshot

    Tiffany earned her PhD in Genetics from North Carolina State University, where she explored the effect of genetic background on the ability to derive induced pluripotent stem cells. She completed her postdoctoral training at the University of North Carolina at Chapel Hill, specializing in the development of translational approaches to direct cardiac reprogramming and understanding the mechanisms of cardiomyocyte maturation. She has written for multiple medical, nonprofit, and academic peer-reviewed outlets. In March 2020, Tiffany joined LabX Media Group as an assistant science editor for The Scientist. She began working with Drug Discovery News in October 2020.

Related Topics

Published In

September 2024 front cover
Volume 20 - Issue 5 | September 2024

September 2024

September 2024 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

An illustration of three immune cells attacking a cancer cell, representing the mechanism of chimeric antigen receptor-based cell therapy

Cell therapy's next frontiers

As cell therapy evolves rapidly, what advancements are on the horizon? 
An illustration of a human heart on top of a DNA strand

Reversing rejection: gene therapy in modern transplantation

Emerging gene editing approaches pave the way for safer, more successful transplants.
An 3D illustration of protein molecules in different colors

Identifying druggable therapeutic targets

Effective target identification is central to drug discovery, but finding the right drug target is not as simple as it may seem in theory. 
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue